Investor Factsheet

“Health for all, hunger for none” – putting an end to hunger and helping everyone lead a healthy life, while at the same protecting ecosystems. That’s what we aspire to achieve, guided by our corporate purpose “Science for a better life.” The major issues of our time can only be addressed if we work together. Our campaigns #voranbringen in Germany and “This is why we science” in the United States underscore our approach. We are a life science company and a global leader in health care and nutrition. Our innovative products support efforts to overcome the major challenges presented by a growing and aging global population. We help prevent, alleviate and treat diseases. We also aim to ensure the world has a reliable supply of high-quality  food, feed and plant-based raw materials. As part of this endeavor, the responsible use of natural resources is always a top priority.
We aim to enhance our company’s earning power and create value for customers, patients, shareholders, employees and society. Growth and sustainability are integral parts of our strategy, guided by our corporate values of Leadership, Integrity, Flexibility and Efficiency, or LIFE for short. This culture ensures a common identity throughout the Bayer Group.


Published on February 27, 2020 in the Annual Report 2019:

Key Data Bayer Group 2018 2019
€ million € million
Sales 36,742 43,545
EBITDA1 9,695 9,554
EBITDA before special items1 8,969 11,503
EBITDA margin before special items1 24.4% 26.4%
EBIT1 3,454 4,189
EBIT before special items1 6,013 7,007
Income before income taxes 1,886 2,880
Net income (from continuing and discontinued operations) 1,695 4,091
Earnings per share (from continuing and discontinued operations) (€)1 1.80 4.17
Core earnings per share (from continuing operations) (€)1 5.60 6.40
Net cash provided by operating activities (from continuing and discontinued operations) 7,917 8,207
Free cash flow (€) 4,652 4,214
Net financial debt 35,679 34,068
Capital expenditures (as per segment table) 2,368 2,920

Bayer AG 2018 2019
Total dividend payment 2,611 2,751
Dividend per share (€) 2.80 2.80

Innovation 2018 2019
Research and development expenses 5,105 5,342
Ratio of R&D expenses2 to sales – Crop Science (%) 13.0 11.7
Ratio of R&D expenses2 to sales – Pharmaceuticals (%) 15.5 15.4
Ratio of R&D expenses2 to sales – Consumer Health (%) 4.1 4.2
Employees in research and development 16,835 16,006

Employees 2018 2019
Number of employees3 (Dec. 31) 107,894 103,824
Personnel expenses (including pension expenses) (€ million) 10,778 11,788
Proportion of employees with health insurance (%) 98 98
Fluctuation (voluntary / total) (%) 5.5 / 14.8 6.6 / 15.0
Hours of vocational and ongoing training per employee 17.1 22.6

figures restated; proportion of employees with health insurance: 2018 figures as last reported
1 For definitions of the indicators see A 2.3.
2 R&D expenses before special items
3 Employees calculated as full-time equivalents (FTEs)
4 In 2019, we changed over to the reporting criteria of the International Council of Chemical Associations (ICCA) and now report the discharge of chemical substances or utilities as Process Safety Incidents (PSI). Previously we reported according to the criteria of the European Chemical Association (CEFIC).
5 Quotient of total energy consumption and external sales
6 Direct emissions from power plants, waste incinerators and production plants and indirect emissions from external supplies of electricity, steam and refrigeration (according to the market-based method)



Current Event

February 25, 2021

Annual Report 2020

Add to my calendar


Current Investor News

Bayer Stock

The capital stock of Bayer AG, amounting to Euro 2,515,005,649.92 is divided into 982,424,082 no-par registered shares. The capital stock underlying the no-par value registered shares is evidenced by permanent global certificates deposited with Clearstream Banking AG, Frankfurt am Main, Germany. The Company’s shareholders have ownership in these certificates in proportion to their respective holdings.The current value of one share - the share price - is determined by the company's total value on the stock market (market capitalization) and the number of shares in circulation.

Security Identification No.
Bayer Code
ReutersXetra ®BAYGn.DE
Frankfurter WertpapierbörseBAYGn.F
BloombergXetra ®BAYN GY
Frankfurter WertpapierbörseBAYN GF

Bayer has a significant weighting in virtually all the major stock indices in line with its high market capitalization and share turnover.

Bayer stock is listed on all the German stock exchanges.

Paying and exchange agent for the shares of Bayer AG is Deutsche Bank AG (Taunusanlage 12, 60325 Frankfurt am Main, Germany).

Information about the dividend for fiscal 2019

The Annual Stockholders’ Meeting on April 28, 2020 resolved to use the distributable profit of EUR 2,750,787,429.60 for the fiscal year 2019 to pay a dividend of EUR 2.80 per share on the 982,424,082 no-par shares entitled to the dividend. The dividend yield calculated on the share price at year end 2019 amounts to 3.8 percent.


Stock ownership by region

Our ownership structure is very international, thus also reflecting our company’s global presence. Almost one third (33.2%) of our stock is attributable to investors in North America. Just under one fifth (19.9%) is held by stockholders in Germany. Another significant group of investors is based in the United Kingdom and Ireland; they hold 15.6% of Bayer stock.


Credit Rating

The rating agencies have assigned the following ratings:

Rating agencyLong-term ratingShort-term ratingOutlook
S&P Global RatingsBBBA2stable
Fitch RatingsBBB+F2stable

Future Perspectives

(published on November 3, 2020 in the Quarterly Statement Third Quarter 2020)

Corporate Outlook
Based on the business development described in this Quarterly Statement and our internal planning, we confirm the revised currency-adjusted Group outlook for 2020 that we issued in August of this year.

For 2020, we expect to post sales of €43 billion to €44 billion on a currency-adjusted basis. This corresponds to an increase of 0 to 1% on a currency- and portfolio-adjusted basis. We are targeting an increase in the EBITDA margin before special items to around 28% on a currency-adjusted basis. Based on the sales target, this would correspond to EBITDA before special items of around €12.1 billion on a currency-adjusted basis. We anticipate raising core earnings per share to between €6.70 and €6.90 on a currency-adjusted basis.

However, due to revised growth assumptions, we now expect to post currency- and portfolio-adjusted sales growth of 1% (previously: 2%) at Crop Science and 5% (previously: 4%) at Consumer Health.


Forward-Looking Statements

This fact sheet may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer Investor Relations

Bayer AG
Building W11
51368 Leverkusen
Phone: +49 214 30 72704

Dr. Jürgen Beunink
Senior Manager

Laura Meyer
Senior Manager (U.S.)

Oliver Maier
Investor Relations Lead